Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05390021
Other study ID # 22-112
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date March 30, 2024
Est. completion date February 1, 2026

Study information

Verified date April 2024
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial cancer. The name of the intervention involved in this study is: Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)


Description:

This research study involves undergoing a diagnostic imaging procedure called positron emission tomography/magnetic resonance imaging (PET/MRI). This type of scan uses a powerful magnet and a special drug that emits a small but detectable amount of radiation to show detailed images of tumors. This study, will examine the diagnostic effectiveness of positron emission tomography/magnetic resonance imaging (PET/MRI), which will be the intervention. The study will compare the results of this scan to either the computed tomography (CT) or PET/CT that participants would normally undergo as a standard of care for high-risk endometrial cancer. The research study procedures include a screening for eligibility and a single study visit. - Participants will undergo the PET/MRI in one study visit of approximately four hours. - It is expected that about thirty-three (33) people will take part in this research study. The U.S. Food and Drug Administration (FDA) has approved the PET/MRI scanner as a diagnostic modality option for indications that include for high-risk endometrial cancer.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 1, 2026
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Women aged 18-85 years old with an endometrial biopsy-confirmed diagnosis of either grade 3 endometrioid, serous, carcinosarcoma, undifferentiated or mixed cell carcinoma - Must have presumed stage I disease, i.e., no symptoms suggesting disease outside of the uterus (weight loss, early satiety, bloating, changes in bowel movement, etc.) - Planning to undergo cytoreductive surgery with a Gynecologic oncologist employed by Massachusetts General Hospital - No previous history of chronic severe renal insufficiency and a glomerular filtration rate of >30 mL/min/1.73m2. If the patient has a history of acute renal failure but their GFR as recovered to above 30, Exclusion Criteria: - Weight greater than 300lbs (the PET/MRI table weight limit) or BMI > 33 - Subjects less than 18 years of age or greater than 85 years of age - Has Electrical implants, such as cardiac pacemakers or perfusion pumps - Has Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, prosthetic heart valves that are not compatible with the gradient maps of our scanners, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants not compatible with a 3 Tesla MR. - Is actively anticipating being pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required on the day of the scan before the subject can participate) - Suffers from claustrophobia - If research-related radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months) - Is unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis) - Subject is under the direct professional supervision of the principal investigator - A history of chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2) - Perioperative liver transplantation period

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with a metastatic lesion noted on PET/MRI that have a true malignancy noted on surgical pathology of that lesion Sensitivity of PET/MRI to detect metastatic lesions Baseline
Primary Percentage of patients without any metastatic lesion noted on PET/MRI that do not have malignancy noted on surgical pathology Specificity of PET/MRI to detect abscence of metastatic lesions Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05063019 - Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer Index N/A
Recruiting NCT05597683 - Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy N/A
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Completed NCT02189434 - Does Serum Procalcitonin Levels Predict Sepsis in Patients Undergoing Cytoreductive Surgery N/A
Not yet recruiting NCT05353582 - Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases Phase 2
Recruiting NCT05939193 - Effect of Urine-guided Hydration on Acute Kidney Injury After CRS-HIPEC N/A
Completed NCT06398678 - Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Not yet recruiting NCT05633199 - Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer N/A
Completed NCT03646474 - Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC N/A
Completed NCT04981639 - TAP and IMS for HIPEC Phase 3
Completed NCT04744688 - Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Recruiting NCT05942209 - ECO-LEAK Technique: Early Detection of Colorectal Anastomotic Leakage by Transvaginal Ultrasound